PMID: 11909836Mar 23, 2002Paper

Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae

The Journal of Antimicrobial Chemotherapy
H LindeN Lehn

Abstract

The mechanisms of fluoroquinolone resistance in two isolates of Enterobacter cloacae, Ecl#1 and Ecl#2, from the same patient and with identical pulsed-field gel electrophoresis patterns, have been analysed. MICs of ciprofloxacin were 0.25 and 1 mg/L for Ecl#1 and Ecl#2, respectively. Ecl#2 was also more resistant to chloramphenicol and organic solvents. The quinolone resistance determining regions of gyrA/B and parC/E, and the marORA and acrB genes, were sequenced. Expression of marR, acrB, soxS, robA, ramA and fis was analysed by northern blotting. The activity of a 90 bp E. cloacae mar promoter fragment was examined with the reporter plasmid pIGJ-1mar. Sequencing the gyrAB and parCE genes revealed a single amino acid substitution in GyrA (corresponding to position 83 in GyrA of Escherichia coli) in Ecl#1 and Ecl#2 (Phe83) compared with reference strain E. cloacae DSMZ 3264 (Thr83). Ecl#2 accumulated significantly less norfloxacin and displayed higher levels of expression of marR and acrB than Exl#1, indicative of greater fluoroquinolone efflux activity. Sequencing gyrB, parC/E and marORA, and northern blotting of robA, ramA and fis, did not reveal any further differences between the two strains. No homologue of soxRS was dete...Continue Reading

References

Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·R G Martin, J L Rosner
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·M N Alekshun, S B Levy
Jul 14, 1998·Antimicrobial Agents and Chemotherapy·L Martínez-MartínezA Pascual
Aug 4, 1998·Antimicrobial Agents and Chemotherapy·M OethingerS B Levy
Oct 3, 1998·Antimicrobial Agents and Chemotherapy·L M WeigelF C Tenover
Jan 27, 1999·Journal of Medical Microbiology·C DekitschA Georgopoulos
Sep 28, 1999·Trends in Microbiology·M N Alekshun, S B Levy
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·W V KernS B Levy

❮ Previous
Next ❯

Citations

Jun 9, 2005·Advanced Drug Delivery Reviews·Ayush Kumar, Herbert P Schweizer
May 29, 2008·Antimicrobial Agents and Chemotherapy·Yingmei FuFengmin Zhang
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Melissa A VisalliPatricia A Bradford
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Renaud CholletAnne Davin-Regli
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Alexey RuzinPatricia A Bradford
Jan 14, 2004·Drugs·Xian-Zhi Li, Hiroshi Nikaido
Jan 27, 2007·International Journal of Antimicrobial Agents·Christine LascolsEmmanuelle Cambau
Jan 7, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·K Poole
May 26, 2005·The Journal of Antimicrobial Chemotherapy·Keith Poole
Jul 19, 2019·Clinical Microbiology Reviews·Anne Davin-RegliJean-Marie Pagès

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.